Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-06-07
1999-02-23
Guzo, David
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
435 71, 435 72, 5303871, 5303881, 5303882, 5303913, A61K 39395, C07K 1628, G01N 3353
Patent
active
058744002
ABSTRACT:
Nucleic acid molecules encoding the C140 cell surface receptor have been cloned and sequenced. The availability of C140 receptor DNA permits the recombinant production of the C140 receptor which can be produced on the surface of a cell, including an oocyte. The nucleic acid molecules are useful in an assay for detecting a substance which affects C140 receptor activity, either receptor agonists or antagonists. Further, the elucidation of the structure of the C140 receptor permits the design of agonist and antagonist compounds which are useful in such assays. The availability of the C140 receptor also permits production of antibodies specifically immunoreactive with one or more antigenic epitopes of the C140 receptor.
REFERENCES:
patent: 5128254 (1992-07-01), Sibley et al.
Patel et al. "Mini Review: The Somatostatin Receptor Family," Life Sciences 5(13) 11 Jul. 1995:1249-1265.
Horuk, "Molecular properties of the chemokine receptor family," TiPS May 1994, 151(5):159-165.
R. J. Kaufman, Methods in Enzymology, vol. 185, pp. 487-511 (1990): "Vectors Used for Expression in Mammalian Cells".
Masu et al., Nature, vol. 329, pp. 836-838 (1987): "cDNA Cloning of Bovine Substance-K Receptor Through Oocyte Expression System".
Scarborough et al., The Journal of Biological Chemistry, vol. 267 (19):13146-49 (1982): "Tethered Ligand Agonist Peptides".
Vu et al., Cell, vol. 64, pp. 1057-1068 (1991): "Molecular Cloning of a Functional Thrombin Receptor Reveals a Novel Proteolytic Mechanism of Receptor Activation".
Scarborough Robert M.
Sundelin Johan
COR Therapeutics
Guzo David
LandOfFree
Recombinant C140 receptor, its agonists and antagonists, and nuc does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant C140 receptor, its agonists and antagonists, and nuc, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant C140 receptor, its agonists and antagonists, and nuc will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-306876